Xencor: Q3 Earnings Insights
Xencor (NASDAQ:XNCR) reported its Q3 earnings results on Monday, November 8, 2021 at 04:01 PM.
Here's what investors need to know about the announcement.
Xencor Q3 EPS $(0.69) Misses $(0.65) Estimate, Sales $19.68M Beat $19.04M Estimate
Xencor (NASDAQ:XNCR) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.65) by 6.15 percent. This is a 213.64 percent decrease over losses of $(0.22) per share from the same
Earnings Scheduled For November 8, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million.
Preview: Xencor’s Earnings
Xencor (NASDAQ:XNCR) is set to give its latest quarterly earnings report on Monday, 2021-11-08. Here's what investors need to know before the announcement.
Analysts estimate that Xencor will likely report an Earnings Per Share (EPS) of $-0.65
Xencor To Present Data From The Phase 1 Study Of Plamotamab In B-cell Malignancies At The American Society Of Hematology Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that updated clinical
JNJ, Xencor Sign $100M Licensing Deal For B-Cell Malignancies-Targeted Bispecific Antibody
Johnson & Johnson’s (NYSE:JNJ) Janssen unit has inked a licensing deal worth $100 million in upfront cash and $25 million in equity for…
Xencor Enters Global Collaboration And License Agreement With Janssen To Advance Plamotamab And XmAb CD28 Bispecific Antibody Combinations For The Treatment Of Patients With B-Cell Malignancies; Xencor To Receive $100M Upfront Payment And $25M Equity I…
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced an exclusiveXencor, Inc.
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 26)
Return on Capital Employed Insights for Xencor
After pulling data from Benzinga Pro it seems like during Q2, Xencor (NASDAQ:XNCR) earned $9.09 million, a 157.98% increase from the preceding quarter. Xencor also posted a total of $67.45 million in sales, a 98.58% increase since Q1.